ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results…
Oncology
-
-
Oceanpine Capital to acquire 80% equity stake in Beijing Jacoray
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for a total consideration of 200m…
-
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo(cemiplimab-rwlc) as an adjuvant…
-
Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy
Trogenix has raised £70m ($95m) in Series A financing to help bring its “Trojan horse” cancer treatment into clinical trials,…
-
Genmab to acquire Merus shares for $8bn
Genmab has signed an agreement to buy all shares of clinical-stage biotechnology company Merus at $97 per share, in an…
-
Sanofi announces $625m to venture capital arm
Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under management to…
-
EC approves Servier’s Voranigo to treat IDH-mutant glioma
The European Commission (EC) has sanctioned the use of Servier’s Voranigo (vorasidenib) to treat certain brain tumours, specifically non-enhancing grade…
-
GSK plans $30bn investment for R&D in US
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D)…
-
Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia…
-
Health Canada approves AbbVie’s Elahere for ovarian cancer
Health Canada has approved AbbVie's antibody-drug conjugate (ADC), Elahere (mirvetuximab soravtansine for injection), to treat adults with certain types of…
